Eli Lilly Stock Dips Amid Mixed GLP-1 Prescription Data

Stock Reacts to Weekly Drug Performance

Eli Lilly and Company (NYSE:LLY) shares experienced a 2% decline following the release of weekly prescription data that revealed a mixed performance across its popular GLP-1 drug portfolio. While some products showed growth, a slight overall dip in total prescriptions influenced investor sentiment.

Prescription Data Overview

According to IQVIA data, for the week of April 17, 2026, Mounjaro total prescriptions increased to approximately 758,400. However, Zepbound total prescriptions saw a slight decrease to 615,300 from 632,500 the previous week. The combined total prescriptions for key drugs including Mounjaro, Trulicity, and Zepbound declined by 0.3% week-over-week. The newly launched Foundayo recorded about 3,700 prescriptions in its second week.

Market Position and Future Outlook

Despite the weekly fluctuation, Eli Lilly maintained its dominant market position, holding approximately 59% of the weekly new prescription share in the GLP-1 category, which itself grew about 32% year-over-year. Analysts from Morgan Stanley noted they see potential upside for Mounjaro and Zepbound 2026 estimates, highlighting the ongoing monitoring of these key product launches as crucial for the company's growth trajectory.

Summary

The minor dip in Eli Lilly's stock reflects a nuanced reaction to complex weekly data. While the company's long-term market share and the overall growth of the GLP-1 category remain strong, investors are closely watching the performance of Zepbound and the market entry of new products like Foundayo.

FAQ

Q: Why did Eli Lilly's stock fall despite Mounjaro's growth?
A: The stock fell due to mixed overall results. A slight decline in total prescriptions for Zepbound and the combined GLP-1 portfolio offset the gains from Mounjaro, leading to a cautious market reaction.

Q: What is Eli Lilly's current market share in the GLP-1 drug category?
A: Eli Lilly holds a substantial market share of approximately 59% for weekly new prescriptions within its GLP-1 franchise, which includes Mounjaro, Trulicity, and Zepbound.

Source: Investing.com